Dr. Robert C. O'Laughlin, MD

Dr. O'Laughlin practices at Southwest Oncology Centers in Scottsdale, Arizona.

Dr. O'Laughlin's NPI, 1699841254, was assigned on November 27, 2006. Dr. O'Laughlin holds Nevada license 12398.

Dr. O'Laughlin's primary practice is Southwest Oncology Centers, at 2926 N Civic Center Plz, Scottsdale, AZ 85251 in Maricopa County. The practice phone is (480) 614-6300.

Dr. O'Laughlin's primary practice is Southwest Oncology Centers in Scottsdale, Arizona. The medical group on file is Southwest Oncology Centers. Dmand AI also links Dr. O'Laughlin to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. O'Laughlin practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. O'Laughlin's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. O'Laughlin's licenses on file in 3 states: Nevada, Hawaii and Kentucky.

CMS data shows 2,404 Medicare services from Dr. O'Laughlin across 12 procedure codes in 2024, for 77 Medicare patients. Medicare paid $448,212 for them. Every service was in an office.

CMS counts 77 Medicare patients who saw Dr. O'Laughlin in 2024. The largest group is 65 to 74, with 39 patients. 75% of them have cancer, and 73% have high cholesterol. Their average risk score is 1.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. O'Laughlin's median patient age at 73, with 29% women.

In 2024, Dr. O'Laughlin wrote 84 Medicare Part D claims for 37 patients. 93% of them were for generic drugs. CMS names the drug for 38 of them, across 1 drug with 11 or more claims each, at $544 in total drug cost. In 2023, CMS named 62 claims across 3 drugs.

Dr. O'Laughlin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. O'Laughlin as offering telehealth.

CMS Open Payments shows 109 general payments to Dr. O'Laughlin from 37 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $271.